The process of gathering information, verifying facts and assessing risks associated with a business transaction is called “due diligence”. A key challenge in any due diligence is how to gather, verify and evaluate this information within the time and budgetary constraints of the transaction.
Prior to embarking on any due diligence with an intellectual property (IP) component, it is useful if not imperative to understand the following:
- What is the nature of the transaction? Is it a license agreement, an acquisition, a merger, an investment or an IPO?
- Is there specific technology considered key to the deal? Is access to specific technology or a product line driving this deal?
- With respect to any key technology, where is it on the patent life cycle? Has it been patented? Is it an FDA approved product ? Is access to manufacturing key to the deal?
- Is the owner of the technology a publicly-traded company subject to the Sarbanes-Oxley Act of 2002?
- Is the market for the technology domestic or foreign, or both?
Read the complete article by clicking on the link below.
Author(s)
Related Insights
July 23, 2025
Foley Viewpoints
The One Big Beautiful Bill and Workplace Immigration Enforcement
The “One Big Beautiful Bill Act,” signed into law by President Trump on July 4, 2025, will fund government efforts to continue to…
July 23, 2025
Health Care Law Today
Update: CMS Extends Skilled Nursing Facilities’ Medicare Revalidation Deadline
On April 17, 2025, the Centers for Medicare and Medicaid Services (CMS) announced another extension of the deadline by which skilled nursing facilities (SNFs) must revalidate their Medicare enrollments.
July 22, 2025
Health Care Law Today
GLP-1 Receptor Agonists: Clinical Trial Considerations
The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide (Victoza®), semaglutide (Ozempic®, Wegovy®), and tirzepatide (Mounjaro®, Zepbound®).